Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.65 |
| ▸ | ULK1 | O75385 | 1/20 | 0.65 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.65 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | FES | P07332 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | BCR | P11274 | 1/20 | 0.65 |
| ▸ | BRAF | P15056 | 1/20 | 0.65 |
| ▸ | NQO2 | P16083 | 1/20 | 0.65 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.65 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | CLK3 | P49761 | 1/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580405 | 0.91 | AURKA (0.77) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581324 | 0.89 | AURKA (0.70) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580785 | 0.89 | AURKB (0.79) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581667 | 0.88 | AURKA (0.69) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580633 | 0.87 | AURKA (0.65) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581141 | 0.86 | AURKA (0.68) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581472 | 0.85 | AURKA (0.66) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580503 | 0.85 | AURKA (0.64) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581199 | 0.85 | AURKA (0.66) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581458 | 0.85 | AURKA (0.72) | AURKAAURKBULK1RPS6KA5RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885ULK1 572/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | AURKA 2/4885AURKB 4/4885ULK1 467/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885ULK1 572/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885ULK1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.